



Genmab Appoints Margarida Duarte as General Manager, Europe and Emerging Markets

Copenhagen, Denmark – April 1, 2026

- Margarida Duarte joins Genmab as the company expands its commercialisation capabilities in Europe and prepares for future launches
- Margarida brings more than 20 years of international biotech leadership experience across oncology, haematology and rare diseases

Genmab A/S (Nasdaq: GMAB) today announced the appointment of Margarida Duarte as General Manager, Europe and Emerging Markets, as the company continues to scale its commercialisation presence to bring its innovative antibody-based medicines to more patients with cancer.

Founded in 1999 in Copenhagen, Genmab is an international biotechnology company specialising in antibody-based medicines. As part of its continued expansion, Genmab has appointed Margarida Duarte to lead its commercial business in Europe and Emerging Markets. In this role, she will oversee business operations across these commercial markets, with responsibility for driving alignment, performance and launch excellence to advance the company's mission to improve the lives of patients with cancer and other serious diseases.

"We are very pleased to welcome Margarida to Genmab at an important stage in our growth," said Brad Bailey, Executive Vice President and Chief Commercial Officer of Genmab. "Margarida's proven ability to build and scale high-performing organisations, deliver successful oncology launches across complex markets, and lead through transformation make her exceptionally well suited to accelerate our momentum in Europe and expand our impact for patients."

Margarida joins Genmab with more than 20 years of international leadership experience in the biotech sector with a specialised focus in oncology. Most recently, she served as Executive Vice President and Chief Commercial Officer at Deciphera Pharmaceuticals, where she was responsible for commercialisation across U.S., Europe and distributor markets. She led the company's transition to a multiproduct organisation.

Earlier in her career, Margarida held senior leadership roles at Alnylam Pharmaceuticals, Exelixis, Onyx Pharmaceuticals and Amgen, where she led European commercialisation strategies, built high-performing teams and oversaw major oncology launches across diverse healthcare systems.

"I am proud to join Genmab, a company recognised for its pioneering antibody science and strong commitment to patients," said Margarida Duarte. "I look forward to partnering with colleagues across our markets and engaging with external stakeholders to help broaden the impact of our innovative antibody-based medicines for patients."

Margarida will be based at the company's European commercialisation headquarters in Zug, Switzerland, and will report to Brad Bailey, Executive Vice President and Chief Commercial Officer.

About Genmab

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immunomodulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.



Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit us on Genmab.com follow us on [LinkedIn](#) and [X](#).

Contact

Caitlin Craparo, Vice President, Global Commercialisation Communications
T: +1 609 255 7397; E: cacr@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on Genmab’s website under Investor Relations and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at the website of the US Securities and Exchange Commission. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.